Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.35 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.34 |
| ▸ | SLC7A5 | Q01650 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MMP2 | P08253 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.33 |
| ▸ | MMP13 | P45452 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HRH1 | P35367 | 2/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.32 |
| ▸ | DRD3 | P35462 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3440572 | 1.00 | ADAMTS4 (0.35) | ADAMTS4GABRR1SLC7A5TP53MMP2 | |
| SCHEMBL10207190 | 0.84 | TP53 (0.38) | TP53HTR2AHRH1CHRM1AKR1A1 | |
| SCHEMBL17772985 | 0.84 | ALDH1A1 (0.38) | TP53HTR2AHRH1CHRM1AKR1A1 | |
| SCHEMBL11581638 | 0.82 | CHRM1 (0.34) | ADAMTS4GABRR1SLC7A5TP53MMP2 | |
| SCHEMBL11581636 | 0.82 | CHRM1 (0.34) | ADAMTS4GABRR1SLC7A5TP53MMP2 | |
| SCHEMBL21566478 | 0.81 | CHRM2 (0.31) | CHRM1CHRM3 | |
| SCHEMBL19292871 | 0.79 | CHRNB2 (0.31) | TDP1 | |
| SCHEMBL11582618 | 0.79 | TP53 (0.38) | ADAMTS4GABRR1SLC7A5TP53MMP2 | |
| SCHEMBL11582621 | 0.79 | TP53 (0.38) | ADAMTS4GABRR1SLC7A5TP53MMP2 | |
| SCHEMBL14625507 | 0.79 | CHRNB2 (0.31) | TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012004287-A1 | 5-(BIPHENYL-4-YL)-3-PHENYL-1,2,4-OXADIAZOLYL DERIVATIVES AS LIGANDS ON THE SPHINGOSINE 1-PHOSPHATE (S1P) RECEPTORS | MERCK SERONO S.A. (CH) | 2012-01-12 | — | — | WO | disclosed |
| US-7807779-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2010-10-05 | — | — | US | disclosed |
| US-20080234205-A1 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-09-25 | — | — | US | disclosed |
| US-7368528-B2 | Antineoplastic peptides | ABBOTT GMBH & CO. KG (DE) | 2008-05-06 | — | — | US | disclosed |
| US-20060009392-A1 | Salt with physiologically tolerated acid; resistant to enzymatic degradation; oral administration | ABBOTT GMBH & CO., KG. (US) | 2006-01-12 | — | — | US | disclosed |
| EP-1593686-A1 | Antineoplastic peptides | Abbott GmbH & Co. KG (DE) | 2005-11-09 | — | — | EP | disclosed |
| EP-0866800-B1 | ANTINEOPLASTIC PEPTIDES | ABBOTT GMBH & CO KG (DE) | 2004-09-22 | — | — | EP | disclosed |
| EP-0981358-B1 | DOLASTATIN-15 DERIVATIVES IN COMBINATION WITH TAXANES | BASF AG (DE) | 2003-05-28 | — | — | EP | disclosed |
| EP-1021200-B1 | METHODS AND COMPOSITIONS FOR TREATING RHEUMATOID ARTHRITIS | BASF AG (DE) | 2002-02-06 | — | — | EP | disclosed |
| EP-0981358-A1 | DOLASTATIN-15 DERIVATIVES IN COMBINATION WITH TAXANES | BASF AKTIENGESELLSCHAFT (DE) | 2000-03-01 | — | — | EP | disclosed |
| EP-0866800-A2 | ANTINEOPLASTIC PEPTIDES | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-30 | — | — | EP | disclosed |
| WO-1998040092-A1 | DOLASTATIN-15 DERIVATIVES IN COMBINATION WITH TAXANES | BASF AKTIENGESELLSCHAFT (DE) | 1998-09-17 | — | — | WO | disclosed |
| WO-1997022621-A2 | ANTINEOPLASTIC PEPTIDES | BASF AKTIENGESELLSCHAFT (DE) | 1997-06-26 | — | — | WO | disclosed |
| US-4069385-A | FROM AN OLEFIN AND AN ORGANIC PEROXIDE WITH COPPER-SCHIFF BASE COMPEX AS CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JA) | 1978-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080234205-A1 | Antineoplastic peptides | BCL2A1, ETF1, BAK1 | ADAMTS4 3582/4885GABRR1 933/4885SLC7A5 3143/4885 |
| US-20060009392-A1 | Salt with physiologically tolerated acid; resistant to enzymatic degradation; oral administration | CTRB1, CTRB2, BCKDK | ADAMTS4 1836/4885GABRR1 897/4885SLC7A5 820/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.